Observational study · people

SS-31: 79.7 m better walk test vs untreated in Barth syndrome

Checked against the paper Observational studyPublished by PepVault

The takeaway

In a small, non-randomized comparison, people with Barth syndrome on elamipretide walked farther and were stronger over about 64 to 76 weeks than matched untreated patients.

Kind
Observational study
Studied in
People
Published
2022
Journal
Orphanet J Rare Dis

What they tested

The team wanted to know whether people with Barth syndrome who took elamipretide did better over time than similar people who were never treated.

How the study was done

A retrospective, non-interventional comparison of 8 patients from the open-label extension of the TAZPOWER trial, who took 40 mg of elamipretide daily, with 19 untreated patients from a natural history group (people followed without treatment). The groups were compared using a propensity score model, a statistical way to match patients with similar traits.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

On the 6-minute walk test, the main measure, the treated group did better by 79.7 m at week 64 (P = 0.0004) and by 91.0 m at week 76 (P = 0.0005). Muscle strength measured by handheld dynamometry was higher with elamipretide by 40.8 Newtons at 64 weeks and 56.7 Newtons at 76 weeks. The treated group also improved on a 5 times sit-to-stand test and on a multi-domain responder index, a combined score across several measures. Left ventricular stroke volume, the amount of blood the heart pumps per beat, rose from baseline with elamipretide but fell in the untreated group.

What it doesn’t show

This was a small study that looked back at existing records, with only 8 treated patients. The treated patients were not randomly assigned and knew they were on the drug, so the comparison with an untreated group gathered separately is weaker evidence than a placebo-controlled trial.

The paper

Hornby et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022.

The compound

More studies on SS-31

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo